Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

415 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Literature review of visual representation of the results of benefit-risk assessments of medicinal products.
Hallgreen CE, Mt-Isa S, Lieftucht A, Phillips LD, Hughes D, Talbot S, Asiimwe A, Downey G, Genov G, Hermann R, Noel R, Peters R, Micaleff A, Tzoulaki I, Ashby D; PROTECT Benefit-Risk group. Hallgreen CE, et al. Among authors: ashby d. Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):238-50. doi: 10.1002/pds.3880. Epub 2015 Nov 2. Pharmacoepidemiol Drug Saf. 2016. PMID: 26521865 Free article. Review.
Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.
Mt-Isa S, Hallgreen CE, Wang N, Callréus T, Genov G, Hirsch I, Hobbiger SF, Hockley KS, Luciani D, Phillips LD, Quartey G, Sarac SB, Stoeckert I, Tzoulaki I, Micaleff A, Ashby D; IMI-PROTECT benefit-risk participants. Mt-Isa S, et al. Among authors: ashby d. Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):667-78. doi: 10.1002/pds.3636. Epub 2014 May 13. Pharmacoepidemiol Drug Saf. 2014. PMID: 24821575 Review.
Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology.
Hallgreen CE, van den Ham HA, Mt-Isa S, Ashworth S, Hermann R, Hobbiger S, Luciani D, Micaleff A, Thomson A, Wang N, van Staa TP, Downey G, Hirsch I, Hockley K, Juhaeri J, Metcalf M, Mwangi J, Nixon R, Peters R, Stoeckert I, Waddingham E, Tzoulaki I, Ashby D, Wise L. Hallgreen CE, et al. Among authors: ashby d. Pharmacoepidemiol Drug Saf. 2014 Sep;23(9):974-83. doi: 10.1002/pds.3676. Epub 2014 Jul 5. Pharmacoepidemiol Drug Saf. 2014. PMID: 25043919 Free article.
Recommendations for benefit-risk assessment methodologies and visual representations.
Hughes D, Waddingham E, Mt-Isa S, Goginsky A, Chan E, Downey GF, Hallgreen CE, Hockley KS, Juhaeri J, Lieftucht A, Metcalf MA, Noel RA, Phillips LD, Ashby D, Micaleff A; PROTECT Benefit-Risk Group. Hughes D, et al. Among authors: ashby d. Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):251-62. doi: 10.1002/pds.3958. Epub 2016 Jan 22. Pharmacoepidemiol Drug Saf. 2016. PMID: 26800458 Free article.
Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions.
Pignatti F, Ashby D, Brass EP, Eichler HG, Frey P, Hillege HL, Hori A, Levitan B, Liberti L, Löfstedt RE, McAuslane N, Micaleff A, Noel RA, Postmus D, Renn O, Sabourin BJ, Salmonson T, Walker S. Pignatti F, et al. Among authors: ashby d. Clin Pharmacol Ther. 2015 Nov;98(5):522-33. doi: 10.1002/cpt.203. Epub 2015 Sep 11. Clin Pharmacol Ther. 2015. PMID: 26261064 Free article. Review.
415 results